ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 šŸŽ“. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology šŸ„. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) šŸ“‹. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication ProfileĀ 

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan šŸ—¾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 šŸŽ“. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology šŸ„. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) šŸ‡ÆšŸ‡µ, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor šŸ‘Øā€āš•ļø. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology šŸ„, the Japan Society of Hepatology šŸ†, and the Japan Gastroenterological Endoscopy Society šŸ”¬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases šŸ„, and vascular complications like gastric varices and Budd-Chiari syndrome šŸ«€. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes šŸŽÆ. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

  • Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
  • Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
  • Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
  • The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
  • Solitary Cardiac Metastasis of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome

Mr. Xin Huang|Oncology Pharmaceuticals|Best Researcher Award

Mr. Xin Huang|Oncology Pharmaceuticals|Best Researcher Award

Mr. Xin Huang at Wuhan union hospital,China

PROFILEĀ Ā 

 

scopus

Orcid

Early Academic Pursuits šŸŽ“

Dr. Xin Huang’s academic journey commenced at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, where their dedication to medical and research excellence became evident. Since September 2017, Dr. Huang has pursued a dual degree (M.D., Ph.D.), focusing on the nexus of clinical medicine and groundbreaking research. This rigorous training honed both clinical acumen and investigative prowess, laying the foundation for significant contributions to medical science. Their education encompassed advanced studies in bone and joint diseases, immune inflammation, and regenerative medicine, highlighting a strong commitment to tackling some of the most pressing challenges in healthcare.

Professional Endeavors 🩺

Dr. Xin Huang is currently an Attending Doctor at Union Hospital, Tongji Medical College. In this capacity, they seamlessly integrate patient care with research innovation. Beyond clinical practice, Dr. Huang has contributed to over 38 peer-reviewed publications in high-impact journals, reflecting a commitment to advancing medical knowledge.

Their professional engagements also include editorial roles on the Young Editorial Boards of journals like iMeta, Biomaterials Translational, and Gene Expression. These roles underscore their expertise and standing in the scientific community. Furthermore, Dr. Huang has expanded their horizons internationally through a visiting study at the University of Würzburg, Germany, fostering global collaboration in cutting-edge research.

Contributions and Research Focus šŸ”¬

Dr. Huang’s research portfolio is both diverse and impactful. Their primary focus lies in targeted and precise treatment of bone tumors, particularly through an innovative approach centered on the tumor microenvironment (TME). Key areas of research include:

  • Tumor Microenvironment Exploration: Revealing the characteristics of the TME in bone tumors to understand how these environments support or hinder disease progression.
  • Immune Checkpoint Studies: Investigating immune checkpoints such as PD-L1 to discover how they can be manipulated for therapeutic purposes, especially in immunotherapy.
  • Biomimetic Nanovesicles: Pioneering the construction of biomimetic cell membrane-coated nanovesicles designed to deliver targeted anti-tumor treatments with high precision and minimal side effects.

This work has contributed to new paradigms in treating bone tumors and has significant implications for broader applications in oncology, regenerative medicine, and immunology.

Accolades and Recognition šŸ†

Dr. Xin Huang’s dedication to research and patient care has been widely recognized. With 38 SCI/Scopus-indexed publications and three patents, Dr. Huang has firmly established themselves as a thought leader in their field. Their editorial appointments and membership in prestigious organizations such as the Chinese Medical Doctor Association and the Tumor Precision Therapy Professional Committee of the Chinese Anti-Cancer Association further attest to their standing in the academic and medical community.

Notably, Dr. Huang is a nominee for the Best Researcher Award, a testament to their relentless pursuit of excellence and innovation.

Impact and Influence 🌟

Dr. Huang’s work transcends academic circles, offering tangible benefits for patients and practitioners alike. By revealing the intricacies of the tumor microenvironment and advancing targeted treatments, they have paved the way for more effective therapies with fewer side effects.

Their contributions have also fostered international collaboration, bridging the gap between research communities in China and Europe. As an advocate for interdisciplinary research, Dr. Huang’s efforts have influenced emerging areas such as nanomedicine, tissue engineering, and immune-oncology.

Legacy and Future Contributions šŸŒ

Dr. Xin Huang’s legacy is one of innovation, compassion, and collaboration. As they continue their work in regenerative medicine and oncology, their future goals include:

  • Expanding Clinical Applications: Translating research findings into widely accessible treatments for bone tumors and related conditions.
  • Mentorship and Leadership: Inspiring the next generation of scientists and clinicians by serving as a mentor and role model.
  • Global Health Initiatives: Extending their expertise to address global health challenges, particularly in under-resourced settings.

In summary, Dr. Xin Huang’s journey is characterized by a commitment to excellence in medicine and science. Through their pioneering research, professional dedication, and collaborative spirit, they are poised to leave an enduring impact on the fields of oncology, regenerative medicine, and beyond.

šŸŽ“PublicationĀ 

Injectable hydrogels for Fenton-like Mn2+/Fe2+Ā delivery with enhanced chemodynamic therapy prevent osteosarcoma recurrence and promote wound healing after excision surgery

  • AuthorsĀ  Ā :Wang, L., Guo, H., Zhang, W., Su, Z., Huang, X.
  • JournalĀ  Ā  : Materials Today Bio
  • YearĀ  Ā  Ā  Ā  Ā :2024

Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy

    • AuthorsĀ  Ā : Huang, X., Zhang, W.
    • JournalĀ  Ā  :Small Methods
    • YearĀ  Ā  Ā  Ā  Ā :2024

Macrophage membrane-camouflaged biomimetic nanovesicles for targeted treatment of arthritis

  • AuthorsĀ  Ā : Huang, X., Zhang, W.
  • JournalĀ  Ā  : Ageing Research Reviews
  • YearĀ  Ā  Ā  Ā  Ā :2024

The generation and use of animal models of osteosarcoma in cancer research

  • AuthorsĀ  Ā : Pu, F., Guo, H., Shi, D., Zhang, Z., Shao, Z.
  • JournalĀ  Ā  Ā : Genes and Diseases
  • YearĀ  Ā  Ā  Ā  Ā :2024

Bioinspired nanovesicles released from injectable hydrogels facilitate diabetic wound healing by regulating macrophage polarization and endothelial cell dysfunction

  • AuthorsĀ  Ā : Zhang, W., Yang, X., Huang, X., Chen, L.
  • JournalĀ  Ā  : Journal of Nanobiotechnology
  • YearĀ  Ā  Ā  Ā  Ā :2023

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy at HMC, QU, WHO,Qatar

PROFILEĀ Ā 

orcid

Google scholar

Early Academic Pursuits šŸŽ“

The foundation of this individual’s career is rooted in a strong academic background. Although specific details about early education are not mentioned, the advanced roles undertaken in both pharmaceutical and medical sectors suggest a deep understanding and expertise in pharmacology, clinical pharmacy, and sterile medication preparation. Their professional journey likely began with formal education in pharmacy, complemented by continuous professional development and specialized training. The fact that they were entrusted with high-responsibility roles, such as acting pharmacy director, regulatory manager, and clinical instructor, indicates a robust educational foundation coupled with a commitment to lifelong learning.

Their association with the SAAD Training Institute, affiliated with Duke University, is an important academic highlight. This affiliation points to their exposure to global standards in pharmaceutical education and practices, which undoubtedly shaped their approach to teaching and developing competencies within their professional network.

Professional Endeavors šŸ„

SAAD Specialist Hospital, Saudi Arabia (Dec 2003 – Jun 2006)
This phase of the career showcases the breadth and depth of their professional experience in Saudi Arabia’s healthcare system, particularly within SAAD Specialist Hospital, a prominent medical institution. Initially starting as a Pediatric Clinical Pharmacist in 2003, they quickly rose through the ranks to take on more senior and specialized roles.

  • Education and Development Coordinator (Dec 2005 – Jun 2006): In this role, they focused on the educational advancement of the hospital’s healthcare professionals. This position required overseeing staff training and ensuring adherence to the latest pharmaceutical guidelines and practices, fostering an environment of continual learning and improvement.
  • Aseptic Technology Instructor, SAAD Training Institute (Jun 2004 – Jun 2006): As an instructor, they were responsible for training both pharmacists and non-pharmacists in aseptic techniques, particularly in the preparation of sterile medications. The affiliation with Duke University highlights the high standard of education and training delivered.
  • IV Room Supervisor (Jun 2004 – Jun 2006): Managing the IV Room, they oversaw sterile medication preparation for neonates, pediatric, and adult patients, dealing with complex formulations such as Total Parenteral Nutrition (TPN), chemotherapy drugs, and desensitization protocols.

These roles reflect a strong command over clinical pharmacy, sterile practices, and pharmaceutical education, making them a critical contributor to healthcare improvement in Saudi Arabia.

Governmental Hospital of Tropical Diseases, Ministry of Health, Egypt (Dec 1997 – Dec 2003)
Their role at this governmental hospital in Egypt demonstrates significant leadership and management skills within the pharmaceutical services sector.

  • Inpatient Pharmacist (Dec 1997 – Sep 2002): During this period, they were entrusted with the pharmaceutical care of inpatient services, managing medication therapy and ensuring safe medication administration.
  • Acting Pharmacy Director (Oct 2002 – Dec 2003): As Acting Pharmacy Director, they assumed full authority over the hospital’s pharmacy operations. This role required balancing clinical duties with administrative responsibilities, overseeing drug inventories, ensuring compliance with pharmaceutical regulations, and leading the pharmacy staff.

This progression in Egypt’s healthcare sector speaks to their competence, leadership abilities, and the trust placed in them to manage essential healthcare operations.

CBIC Medical, Pharmaceutical Development, and Consultation Company (Nov 2002 – Dec 2003)
In parallel with their role in Egypt’s healthcare system, they also held a position in CBIC Medical, which involved regulatory and marketing responsibilities in the pharmaceutical sector.

  • Regulatory and Marketing Manager: They were tasked with navigating complex pharmaceutical regulations while overseeing the marketing of medical products. This role required a deep understanding of both the regulatory landscape and market dynamics.
  • Clinical and Marketing Instructor: Leveraging their extensive pharmaceutical knowledge, they conducted training programs for medical representatives, teaching them about new products and re-launched products, as well as imparting advanced marketing strategies.

This role illustrates their ability to work across both clinical and commercial spheres, bridging the gap between product development, regulatory compliance, and market outreach.

Contributions and Research Focus šŸ”¬

While explicit research endeavors are not mentioned, their extensive work in teaching, sterile medication preparation, and regulatory roles highlights a career deeply rooted in evidence-based practices. Their focus on educating healthcare professionals in critical areas like aseptic techniques and sterile medication preparation indicates a dedication to improving healthcare outcomes through rigorous training.

The supervisory roles in sterile medication preparation, particularly for vulnerable populations such as neonates and pediatric patients, point to a keen interest in precision pharmacy and patient safety, areas likely to have been influenced by research in clinical pharmacology.

Accolades and Recognition šŸ…

The trust and leadership roles assigned to them—ranging from being an Acting Pharmacy Director to a supervisor and instructor at the SAAD Specialist Hospital—reflect the high regard in which they were held by their peers and employers. Their instructional role at the SAAD Training Institute, affiliated with Duke University, is a significant marker of their expertise and the recognition they received in the field of pharmaceutical education.

Impact and Influence šŸŒ

Their influence spans multiple facets of healthcare, particularly in the realms of education, clinical pharmacy, and sterile medication practices. Through teaching roles, both at SAAD and CBIC Medical, they shaped the competencies of numerous healthcare professionals, directly impacting patient safety and care quality.

As a supervisor in the preparation of sterile medications, they ensured that some of the most vulnerable patients—neonates and those undergoing chemotherapy—received safe, effective treatments. This role would have had a profound impact on patient outcomes, underscoring their influence in clinical settings.

Legacy and Future Contributions šŸ“œ

Their legacy is marked by the high standards of training and education they provided, particularly in aseptic techniques and sterile medication preparation. The knowledge they imparted to medical representatives and pharmacy staff will continue to influence healthcare practices long after their direct involvement.

šŸŽ“PublicationĀ 

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced …

  • AuthorsĀ  Ā :Jeffrey S Weber, Reinhard Dummer, Veerle de Pril, Celeste LebbĆ©, F Stephen Hodi, MDX010‐20 Investigators
  • JournalĀ  Ā  : Cancer
  • YearĀ  Ā  Ā  Ā  Ā :2013

An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital

  • AuthorsĀ  Ā :Eva RƤmme Bremberg, Christina Hising, Urban NylĆ©n, Hans Ehrsson, Staffan Eksborg
  • JournalĀ  Ā  :Journal of Oncology Pharmacy Practice
  • YearĀ  Ā  Ā  Ā  Ā :2006

The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy

  • AuthorsĀ  Ā : Ahmet S Boşnak, Nevzat Birand, Ɩmer Diker, Abdikarim Abdi, Bilgen Başgut
  • JournalĀ  Ā  :Journal of Oncology Pharmacy Practice
  • YearĀ  Ā  Ā  Ā  Ā :2019

Denosumab in hypercalcemia of malignancy: a case series

  • AuthorsĀ  Ā : Amanda Dietzek, Kelly Connelly, Michael Cotugno, Sylvia Bartel, Anne M McDonnell
  • JournalĀ  Ā  :Journal of Oncology Pharmacy Practice
  • YearĀ  Ā  Ā  Ā  Ā :2015

Chinese herbal medicine for reducing chemotherapy-associated side-effects in breast cancer patients: a systematic review and meta-analysis

  • AuthorsĀ  Ā :Sha Li, Tsz-him So, Guoyi Tang, Hor-Yue Tan, Ning Wang, Bacon Fung Leung Ng, Chris Kam Wa Chan, Edwin Chau-Leung Yu, Yibin Feng
  • JournalĀ  Ā  :Frontiers in Oncology
  • YearĀ  Ā  Ā  Ā  Ā :2020